NCT07030140 2025-06-22Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar CholangiocarcinomaShandong Cancer Hospital and InstitutePhase 2 Not yet recruiting38 enrolled